Biotech investors are searching for the next blockbuster medicine, while pharmaceutical giants are searching for something equally valuable: a replacement for the blockbusters they already own. With patent expirations threatening established revenue streams, promising drug developers are attracting attention from both Wall Street and potential buyers. Advances in obesity, oncology, and other treatment areas are adding to the excitement. The challenge is finding companies whose science, finances, and valuations can withstand scrutiny after the investor presentation ends.
Big Pharma’s Patent Clock Is Getting Louder
For major pharmaceutical companies, patent protection is a powerful advantage with an inconvenient feature: an expiration date. When cheaper competitors enter the market, even a dependable bestseller can become a much less dependable source of growth. Replenishing the pipeline becomes increasingly urgent as that deadline approaches.
That pressure was already showing up in deal activity early in 2026. In a May 1 report, Reuters cited Dealogic figures showing that first-quarter biotech deal value reached $84 billion, compared with $44.4 billion a year earlier. The same report cited a William Blair estimate that more than $300 billion in pharmaceutical revenue faced potential losses of exclusivity over the following five years. That is a considerable amount of business to replace before the patents stop doing the heavy lifting.
By July, the acquisition pace had accelerated further. The Financial Times reported on July 21 that 37 biotech acquisitions worth at least $1 billion had been announced that year, surpassing the previous full-year record of 35, according to Stifel. Separately, LSEG data cited in the report placed biotech deal value at $216 billion, against $118 billion during the corresponding period in 2025.
The investment appeal is understandable. A smaller developer with a differentiated medicine could offer a larger buyer a valuable source of future growth. Still, a busy acquisition market does not turn every clinical-stage company into the next bidding war.
Buyers Prefer Pipelines With a Shorter Route to Revenue
The contents of a deal matter more than its headline price. The Financial Times described growing buyer interest in companies with revenue-generating medicines or treatments approaching launch. For drugmakers facing patent expirations, the commercial timetable matters almost as much as the science.
A medicine that could reach patients soon offers a different proposition from one that still needs years of trials, regulatory reviews, and financing. “Enormous long-term potential” is an easier pitch when the buyer’s existing revenue has time to wait.
Earlier-stage developers can still offer substantial opportunities, but investors need to examine what must happen before their medicines become viable products. Differentiated science, credible development plans, and sufficient funding all matter. A takeover might reward shareholders handsomely, but the company should have a workable future if prospective buyers keep their wallets closed.
The arithmetic also deserves attention from the buyer’s side. Our analysis of Biogen examines how pipeline acquisitions can strengthen a growth outlook while adding earnings charges and execution risk. Filling a pipeline gap can be strategically sensible. Whether the purchase creates shareholder value also depends on the price paid and what happens afterward.
Weight-Loss Drugs Carry Some Very Heavy Expectations
Obesity remains one of biotechnology’s most closely watched markets. A September 30 Reuters overview cited analyst expectations that annual weight-loss drug sales could approach $100 billion over the next decade. The treatments target smaller waistlines; the revenue forecasts are considerably less restrained.
Developers are competing through oral medicines, less frequent injections, and approaches designed to preserve lean mass. These differences could influence which treatments patients prefer, physicians prescribe, and payers cover. Their commercial value, however, depends on convincing clinical evidence and practical benefits.
Convenience alone does not settle the competition. Reimbursement, affordability, manufacturing capacity, and access will help determine how much of the projected demand becomes actual revenue. A large addressable market looks excellent in a presentation. An insurer still wants a reason to pay.
Commercialization also brings challenges beyond competing medicines. An August 28 Financial Times report examined counterfeit weight-loss treatments in the UK, noting that Novo Nordisk had secured an expanded website-blocking order while Eli Lilly was disrupting online sellers of unlicensed products.
Those efforts highlight the importance of trusted distribution and product integrity. Strong demand creates an opportunity for legitimate developers, but it also attracts sellers whose enthusiasm for the market exceeds their interest in regulatory approval.
A Promising Pipeline Still Needs Cash Behind It
Across biotechnology, compelling science needs financial staying power. Profitable companies can be assessed through earnings, cash flow, and the durability of their existing products. Clinical-stage developers require closer attention to cash reserves, spending, and the financing needed to reach meaningful milestones.
A company may have an attractive drug candidate and still leave shareholders facing repeated dilution before it reaches the market. Investors should therefore examine both the next clinical catalyst and the cost of getting there. The laboratory can produce encouraging results; it cannot print working capital.
Our earlier coverage of Viking Therapeutics connects progress in its obesity pipeline with the cash available to fund further development, showing why clinical prospects and financial resources belong in the same assessment.
Billionaire ownership can help identify companies drawing attention from experienced investors. It cannot guarantee a successful trial, secure regulatory approval, or make an expensive stock reasonably priced. Even the most impressive shareholder register gets no special treatment from a clinical endpoint.
The stronger investment candidates combine differentiated science, sufficient funding, and a valuation that allows for uncertainty. A successful trial or acquisition could deliver substantial upside. The investment case should also explain how the company moves forward when development takes longer, financing becomes more expensive, or the anticipated buyer never calls.
CHECK THIS OUT: 10 Best Biotech Stocks Under $10 to Buy Now and Top 6 Small-Cap Healthcare Stocks to Buy Right Now.
Our Methodology
To identify the 10 best biotech stocks to buy according to billionaires, we reviewed financial media sources and stock screeners for U.S.-listed biotechnology companies, selected the 10 with the most bullish billionaire positions in our Q2 2026 holdings database, and ranked them in ascending order by the number of billionaire holders.
CLICK HERE TO READ THE FULL ARTICLE: 10 Best Biotech Stocks to Buy According to Billionaires
Tango Therapeutics Inc. (NASDAQ:TNGX)
Number of Hedge Fund Holders — 66
Number of Billionaire Holders — 21
Tango Therapeutics, Inc. (NASDAQ: TNGX) has sharpened its precision-oncology strategy around vopimetostat, an investigational PRMT5 inhibitor being studied in combination with RAS-targeting medicines.
An October 23 update reported an 82% objective response rate among 22 efficacy-evaluable patients with previously treated, MTAP-deleted and RAS-mutant pancreatic cancer receiving vopimetostat plus daraxonrasib. Median progression-free survival had not been reached, and the reported nine-month progression-free survival rate was 88%.
The findings are encouraging, but their setting matters. This was an early-stage study in a small, selected population, and the combination’s contribution requires evaluation in a larger randomized trial. The results should not be treated as proof of superiority over treatments studied in different patient groups.
CEO Malte Peters said the initial clinical activity had been “confirmed with longer follow-up and in a larger patient population.”
Following regulatory discussions, the company planned to initiate a registrational Phase 3 trial in first-line MTAP-deleted pancreatic cancer during the first half of 2027. The proposed study would compare the combination against standard chemotherapy.
A June 30 balance of approximately $1 billion in cash, cash equivalents, and marketable securities provides resources for that transition. Moving into pivotal development can materially increase spending, making financial preparation important alongside response data.
The supplied earlier analyst coverage highlighted potential combination-therapy revenues. Those remain forecasts dependent on clinical success, approval, and commercial arrangements.
For investors evaluating targeted cancer therapy stocks, the next meaningful question is whether the early response signal can hold up in a controlled study with clinically relevant endpoints.
Ranking rationale: Tango Therapeutics, Inc. (NASDAQ: TNGX) ranks second with 21 billionaire holders. Its combination-treatment data, planned pivotal development, and substantial financial resources support the thesis, while the small early-stage dataset leaves significant work ahead.
YOU MUST READ THIS: 10 Promising Small-Cap Biotech Stocks to Watch
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
